HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Endocrine Month in Review: August 2022

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from August 2022 includes a trial examining time-restricted eating, a pair of FDA decisions, coverage of ADCES 22, and more!

1. Trial Suggests Time-Restricted Eating Could Aid in Weight Loss, Improve Blood Pressure

A 14-week, parallel-arm trial comparing the effects of a TRE approach against a control diet, the results of the randomized trial demonstrate adherence to a TRE diet was a more effective strategy for reducing body weight and improving diastolic blood pressure. The trial, which compared TRE against a standard diet, produced results indicating such an approach was associated with significant differences in weight loss and improvements in blood pressure compared to a typical diet.

2. Omnipod 5 Receives Clearance for Use in Ages 2 and Older with Type 1 Diabetes

The US Food and Drug Administration has awarded clearance to Insulet Corporation for its Omnipod 5 Automated Insulin Delivery System for individuals aged 2 years and older with type 1 diabetes. Less than 7 months after receiving clearance for use in patients with type 1 diabetes aged 6 years and older, the latest clearance was announced by Insulet Corporation on August 22.

3. MYFEMBREE Scores FDA Approval for Endometriosis Pain

On August 5, Pfizer announced the US Food and Drug Administration's approval of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the management of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.

4. ADCES 22 Coverage

Coverage of the Association of Diabetes Care and Education Specialists (ADCES) annual meeting. At the meeting, which was held in Baltimore, MD from August 12-15, our editorial team sat down with experts to discuss the latest updates in diabetes management and recorded 4 on-site episodes of Diabetes Dialogue with special guests, including Korey Hood, PhD, Anastasia Albanese-O’Neill, PhD, Jennifer Clements, PharmD, and David Walton.

5. NSAID Use Linked to Increased Heart Failure Risk in Type 2 Diabetes

Short-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) could increase the likelihood of experiencing a first-time heart failure hospitalization among patients with type 2 diabetes, according to a new study presented at the European Society of Cardiology (ESC) Congress 2022. Results of the study indicated NSAID use was associated with an elevated risk of first-time heart failure hospitalization within 120 days (OR, 1.43 [95% CI, 1.27-1.63]). Results suggested the risk of heart failure hospitalization was observed for use of diclofenac (OR, 1.48 [95% CI, 1.10-2.00]) and ibuprofen (OR, 1.46 [95% CI, 1.26-1.69]), but not with celecoxib and naproxen, which investigators noted could be a result of the small sample size for these NSAIDs.

6. GSA Releases New Toolkit for Obesity Management in Older Adults

On August 16, the Gerontological Society of America released a 63-page provider toolkit aimed at providing clinicians managing older patients with obesity with necessary tools and resources to improve the recognition and treatment of obesity in this patient population. Using a KAER (Kickstart, Assess, Evaluate, and Refer) framework, each of the 4 sections within the toolkit contain subsections on key takeaways, an overview, and optimal approaches to implementation.

7. GnRH Agonists for Prostate Cancer Could Increase CVD Risk in Type 2 Diabetes

A new study underlines the need for heightened awareness and control of cardiovascular risk factors among men with type 2 diabetes treated with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer. An analysis of more than 33,000 men from Swedish national databases, results suggest there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared to those who did not.

Check out previous iterations of our month in review countdowns